Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cilazapril. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 13/20 | 0.75 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | MME | P08473 | 2/20 | 0.55 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.54 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.54 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cilazapril SCHEMBL24961 | 1.00 | ACE (0.75) | ACELMNAMMEABCB11AGTR2 | |
| Cilazapril SCHEMBL6508385 | 1.00 | ACE (0.75) | ACELMNAMMEABCB11AGTR2 | |
| Cilazapril SCHEMBL19469323 | 1.00 | ACE (0.75) | ACELMNAMMEABCB11AGTR2 | |
| Cilazapril SCHEMBL15263653 | 0.99 | ACE (0.73) | ACELMNAMMEABCB11AGTR2 | |
| Cilazapril SCHEMBL10368731 | 0.99 | ACE (0.76) | ACELMNAMMEABCB11AGTR2 | |
| Cilazapril SCHEMBL16290008 | 0.99 | ACE (0.76) | ACELMNAMMEABCB11AGTR2 | |
| Cilazapril SCHEMBL29394939 | 0.99 | ACE (0.76) | ACELMNAMMEABCB11AGTR2 | |
| Cilazapril SCHEMBL24962 | 0.99 | ACE (0.76) | ACELMNAMMEABCB11AGTR2 | |
| Cilazapril SCHEMBL14287315 | 0.99 | ACE (0.76) | ACELMNAMMEABCB11AGTR2 | |
| Cilazapril SCHEMBL10562310 | 0.98 | ACE (0.75) | ACELMNAMMEABCB11AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170304388-A1 | NEW INDICATION OF CARDIOVASCULAR DRUGS FOR PREPARATION OF CANCER INHIBITION PHARMACEUTICAL COMPOSITION | LAUNX BIOMEDICAL CO., LTD. (TW) | 2017-10-26 | — | — | US | claimed |
| EP-4691462-A1 | SILYBIN-CONTAINING COMPOSITION | Tianjin Tasly Sants Pharmaceutical Co., Ltd. (CN) | 2026-02-11 | — | — | EP | disclosed |
| US-20260027215-A1 | COMPOSITIONS FOR TRANSPORT OF THERAPEUTIC CARGOS USING BINDERS TARGETING CA-IV | RECEPTIVE BIO INC (US) | 2026-01-29 | — | — | US | disclosed |
| EP-3763364-B1 | SELF-EMULSIFYING COMPOSITION OF OMEGA-3 FATTY ACID | MOCHIDA PHARM CO LTD (JP) | 2025-11-05 | — | — | EP | disclosed |
| WO-2024199025-A1 | SILYBIN-CONTAINING COMPOSITION | 江苏天士力帝益药业有限公司 | 2024-10-03 | — | — | WO | disclosed |
| CN-118697729-A | Composition containing silybin | 江苏天士力帝益药业有限公司 | 2024-09-27 | — | — | CN | disclosed |
| US-20240279201-A1 | DUAL WNT SIGNALING PATHWAY INHIBITORS AND AMPK ACTIVATORS FOR TREATMENTS OF DISEASE | UNIVERSITY OF MARYLAND, BALTIMORE | 2024-08-22 | — | — | US | disclosed |
| US-20240252646-A1 | SELF-EMULSIFYING COMPOSITION OF OMEGA-3 FATTY ACID | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2024-08-01 | — | — | US | disclosed |
| EP-4346811-A1 | DUAL WNT SIGNALING PATHWAY INHIBITORS AND AMPK ACTIVATORS FOR TREATMENTS OF DISEASE | University of Maryland, Baltimore (US) | 2024-04-10 | — | — | EP | disclosed |
| US-11911480-B2 | Self-emulsifying composition of ω-3 fatty acid | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2024-02-27 | — | — | US | disclosed |
| EP-1889629-B1 | Stable formulation comprising a combination of a moisture sensitive drug and a second drug and manufacturing procedure thereof | TEVA PHARMA (IL) | 2008-08-27 | — | — | EP | disclosed |
| EP-1917973-A1 | Stable formulation comprising a moisture sensitive drug and manufacturing procedure thereof | Teva Pharmaceutical Industries Ltd (IL) | 2008-05-07 | — | — | EP | disclosed |
| EP-1889629-A1 | Stable formulation comprising a combination of a moisture sensitive drug and a second drug and manufacturing procedure thereof | Teva Pharmaceutical Industries Ltd (IL) | 2008-02-20 | — | — | EP | disclosed |
| WO-2008008057-A1 | STABLE FORMULATION COMPRISING A COMBINATION OF A MOISTURE SENSITIVE DRUG AND A SECOND DRUG AND MANUFACTURING PROCEDURE THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-01-17 | — | — | WO | disclosed |
| US-20080008751-A1 | Stable formulation comprising a combination of a moisture sensitive drug and a second drug and manufacturing procedure thereof | TEVA PHARMACEUTICALS USA, INC. | 2008-01-10 | — | — | US | disclosed |
| EP-1864677-B1 | Stable formulation comprising a moisture sensitive drug and manufacturing procedure thereof | TEVA PHARMA (IL) | 2008-01-02 | — | — | EP | disclosed |
| WO-2007142628-A1 | STABLE FORMULATION COMPRISING MOISTURE SENSITIVE DRUG/S AND MANUFACTURING PROCEDURE THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-12-13 | — | — | WO | disclosed |
| EP-1864677-A1 | Stable formulation comprising a moisture sensitive drug and manufacturing procedure thereof | Teva Pharmaceutical Industries Ltd (IL) | 2007-12-12 | — | — | EP | disclosed |
| US-20070281000-A1 | Stable formulation comprising moisture sensitive drug/s and manufacturing procedure thereof | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-12-06 | — | — | US | disclosed |
| WO-2005003134-A1 | A NOVEL PROCESS FOR THE PREPARATION OF CILAZAPRIL | HETERO DRUGS LIMITED (IN) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080008751-A1 | Stable formulation comprising a combination of a moisture sensitive drug and a second drug and manufacturing procedure thereof | ACE, CMA1, ACE2 | ACE 1/4885LMNA 2980/4885MME 8/4885 |
| US-20240279201-A1 | DUAL WNT SIGNALING PATHWAY INHIBITORS AND AMPK ACTIVATORS FOR TREATMENTS OF DISEASE | PRKAB2, PRKAB1, PRKAG2 | ACE 4408/4885LMNA 2774/4885MME 4585/4885 |
| US-20260027215-A1 | COMPOSITIONS FOR TRANSPORT OF THERAPEUTIC CARGOS USING BINDERS TARGETING CA-IV | CA4, FLT4, CAMK4 | ACE 380/4885LMNA 3941/4885MME 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.